Search results
Results from the WOW.Com Content Network
Proprietary database identifiers include those assigned by First Databank, Micromedex, MediSpan, Gold Standard Drug Database (published by Elsevier), and Cerner Multum MediSource Lexicon; these are cross-indexed by RxNorm, which also assigns a unique identifier (RxCUI) to every combination of active ingredient and dose level.
To arrive at their findings, researchers searched a database of about 42,000 recipes for oral medications in the U.S. and found that close to 93 percent contained at least one of 38 inactive ...
The Unique Ingredient Identifier (UNII) is an alphanumeric identifier linked to a substance's molecular structure or descriptive information and is generated by the Global Substance Registration System (GSRS) of the Food and Drug Administration (FDA).
The International Numbering System for Food Additives (INS) is an international naming system for food additives, aimed at providing a short designation of what may be a lengthy actual name. [1]
The drug must be combined with inactive ingredients by a method that ensures that the quantity of drug present is consistent in each dosage unit e.g. each tablet. The dosage should have a uniform appearance, with an acceptable taste, tablet hardness, and capsule disintegration.
For single-ingredient records, Seq1=01 identifies a specific active moiety. If Seq1 is higher than 01 it refers to variations of that active moiety. For multi-ingredient records, Seq1=01 identifies a combination of active moieties. If Seq1 is higher than 01 it refers to variations of one or more of the active moieties in the combination.
An International Nonproprietary Name (INN) is an official generic and nonproprietary name given to a pharmaceutical substance or an active ingredient, [1] encompassing compounds, peptides and low-molecular-weight proteins (e.g., insulin, hormones, cytokines), as well as complex biological products, such as those used for gene therapy. [2]
In the United States, DMFs are submitted to the Food and Drug Administration (FDA). The Main Objective of the DMF is to support regulatory requirements and to prove the quality, safety and efficacy of the medicinal product for obtaining an Investigational New Drug Application (IND), a New Drug Application (NDA),As an Abbreviated New Drug Application (ANDA), another DMF, or an Export Application.